Showing 1 posts of 1 posts found.
AstraZeneca has signed an agreement to develop and commercialise a cancer nanomedicine from US firm Bind Therapeutics’ stable of Accurins. …
Qureight paper argues for fibrosis extent as imaging biomarker in lung disease trials
START and Rome cancer institute partner to expand early-phase trial access in Italy
AbbVie expands Oxford R&D facility with new £120m UK research commitment
MedPharm appoints Jason Mieding as chief operating officer
UKRI backs five hubs developing AI tools for earlier disease detection